MedTrace Logo

Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.

NCT06130384 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2024-02-09

No results posted yet for this study

Summary

The purpose of this prospective interventional study is to compare post-intravitreal injection pain between eyes receiving topical bromfenac versus artificial tears as an analgesic after intravitreal injection.

Conditions

  • Pain
  • Intravitreal Injection
  • Pain, Acute

Interventions

DRUG

Use of bromfenac 0.09% to reduce intravitreal injection pain

The eyedrop (bromfenac) will be given to the assigned eye.

DRUG

Use of artificial tears to reduce intravitreal injection pain

The eyedrop (artificial tears) will be given to the assigned eye.

Sponsors & Collaborators

  • Wills Eye

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2023-08-15
Completion
2023-11-15
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06130384 on ClinicalTrials.gov